Valuation: Spyre Therapeutics, Inc.

Market Cap 9.23B 8.02B 7.48B 6.87B 12.99B 878B 13.13B 88.13B 34.45B 439B 34.67B 33.91B 1,455B P/E 2026 *
-34.7x
P/E 2027 * -31.4x
Enterprise Value 8.65B 7.51B 7.01B 6.44B 12.17B 823B 12.31B 82.6B 32.29B 411B 32.5B 31.78B 1,363B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
1 day+10.54%
1 week+4.98%
Current month+6.72%
1 month+21.14%
3 months+51.80%
6 months+227.22%
Current year+220.33%
1 week 92.71
Extreme 92.71
105.25
1 month 86.6
Extreme 86.6001
105.25
Current year 28
Extreme 28
105.25
1 year 14.5
Extreme 14.505
105.25
3 years 8.43
Extreme 8.43
105.25
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 2023-11-26
Director of Finance/CFO 49 2023-08-31
Chief Tech/Sci/R&D Officer - 2023-11-26
Director TitleAgeSince
Director/Board Member 36 2023-11-26
Director/Board Member 39 2023-06-21
Director/Board Member 36 2023-06-21
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Chief Executive Officer

-15,000 0.0173%
7/1/26 Fiscal year

Chief Technology Officer

25,002 0.0288%
7/1/26 Fiscal year

Chief Financial Officer

22,500 0.0259%
Change 5-day change 1-year change 3-year change Capi.($)
+10.54%+4.98%+549.38%+774.32% 8.35B
+10.00%+14.90%+53.89%+87.07% 56.7B
+0.80%-5.70%+23.89%+62.65% 51.97B
-0.98%-1.19%-16.98%-14.21% 23.33B
+0.30%-5.17%-11.23%+349.07% 21.34B
+1.73%-1.57%+32.81%-25.80% 17.44B
+4.29%+8.97%+200.03%+341.85% 14.77B
+2.66%-0.76%+14.04%+615.65% 14.53B
+1.71%-0.90%+52.13%+176.27% 13.84B
+4.16%+4.44%+444.12%+183.06% 12.12B
Average +3.50%+1.03%+134.21%+254.99% 23.44B
Weighted average by Cap. +3.77%+1.44%+77.14%+170.57%

Financials

2026 *2027 *
Net sales - -
Net income -267M -232M -216M -198M -375M -25.36B -379M -2.55B -995M -12.68B -1B -979M -42.01B -306M -265M -247M -227M -430M -29.08B -435M -2.92B -1.14B -14.54B -1.15B -1.12B -48.16B
Net Debt -580M -503M -469M -431M -815M -55.15B -824M -5.53B -2.16B -27.57B -2.18B -2.13B -91.34B -485M -421M -393M -361M -682M -46.12B -690M -4.63B -1.81B -23.06B -1.82B -1.78B -76.4B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
112
Date Price Change Volume
26-08-04 US$104.94 +10.54% 831,929
26-08-03 US$94.93 -3.46% 898,396
26-07-31 US$98.33 -3.12% 621,726
26-07-30 US$101.50 +3.71% 851,502
26-07-29 US$97.87 -2.09% 1,216,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
104.94USD
Average target price
105.79USD
Spread / Average Target
+0.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock